[1]张书萌,陈伶利,张湘卓,等.基于DNA甲基化/羟甲基化水平中药调控冠心病血瘀证相关基因分子生物学研究进展[J].中国中医药信息杂志,2020,27(11):141-144.[doi:10.19879/j.cnki.1005-5304.202005437]
 ZHANG Shumeng,CHEN Lingli,ZHANG Xiangzhuo,et al.Research Progress in Molecular Biology of TCM Regulating Coronary Heart Disease with Blood Stasis Syndrome-related Genes Based on DNA Methylation/Hydroxymethylation Levels[J].zhongguo zhongyiyao xinxi zazhi,2020,27(11):141-144.[doi:10.19879/j.cnki.1005-5304.202005437]
点击复制

基于DNA甲基化/羟甲基化水平中药调控冠心病血瘀证相关基因分子生物学研究进展

参考文献/References:

[1] BENJAMIN E J, VIRANI S S, CALLAWAY C W, et al. Heart disease and stroke statistics-2018 update: A report from the American Heart Association[J]. Circulation,2018,137(12):e67-e492.

[2] ZHAO D, LIU J, WANG M, et al. Epidemiology of cardiovascular diseasein China:current features and implications[J]. Nat Rev Cardiol,2019,16(4):203-212.

[3] 陈悦,李杰,陈伶利,等.冠心病血瘀证与DNA甲基化/羟甲基化关系及研究进展[J].湖南中医药大学学报,2018,38(9):1077-1081.

[4] INOUYE M, ABRAHAM G, NELSON C P, et al. Genomic risk prediction of coronary artery disease in 480,000 adults:implications for primary prevention[J]. J Am Coll Cardiol,2018,72(16):1883-1893.

[5] 胡鸣颖,徐耕.冠心病遗传变异研究方法的进展[J].心脑血管病防治, 2015,15(5):401-405.

[6] MAHROOZ A, MACKNESS M, BAGHERI A, et al. The epigenetic regulation of paraoxonase 1 (PON1) as an important enzyme in HDL function:The missing link between environmental and genetic regulation[J]. Clin Biochem,2019,73:1-10.

[7] LI B, FENG Z H, SUN H, et al. The blood genome-wide DNA methylation analysis reveals novel epigenetic changes in human heart failure[J]. Eur Rev Med Pharmacol Sci,2017,21(8):1828- 1836.

[8] HAI Z, ZUO W. Aberrant DNA methylation in the pathogenesis of atherosclerosis[J]. Clin Chim Acta,2016,456:69-74.

[9] KIM M, LONG T L, ARAKAWA K, et al. DNA methylationas a biomarker for cardiovascular disease risk[J]. PLoS One,2010,5(3):e9692.

[10] LI J J, LI Q, DU H P, et al. Homocysteine triggers inflammatory responses in macrophages through inhibiting CSE-H2S signaling via DNA hypermethylation of CSE promoter[J]. Int J Mol Sci,2015, 16(6):12560-12577.

[11] 赖伟华,潘伟祥,冯颖青,等.MeDIP-Seq法检测冠心病患者全基因组甲基化谱[J].中国药房,2015,26(35):4938-4941.

[12] 付龙,孙溢晗,张月兰.MTHFR基因C677T多态性与H型高血压合并冠心病患者HCY、冠状动脉病变的关系[J].中国医科大学学报,2015, 44(4):351-356.

[13] JIA L, ZHU L, WANG J Z, et al. Methylation of FOXP3 in regulatory T cells is related to the severity ofcoronary artery disease[J]. Atherosclerosis,2013,228(2):346-352.

[14] CONNELLY J J, CHEREPANOVA O A, DOSS J F, et al. Epigenetic regulation of COL15A1 in smooth muscle cell replicative aging and atherosclerosis[J]. Hum Mol Genet,2013,22(25):5107-5120.

[15] YANG T C, CHEN Y J, CHANG S F, et al. Malondialdehyde mediates oxidized LDL-induced coronary toxicity through the Akt-FGF2 pathway via DNA methylation[J]. J Biomed Sci,2014,21:11.

[16] 迟映雪.中西医结合治疗对痰浊血瘀型ACS患者MMP-9基因启动子甲基化水平的影响[D].沈阳:辽宁中医药大学,2015.

[17] 李敏,孙杨,邱瑞瑾,等.冠心病相关中医证候DNA甲基化研究进展[J].中国中西医结合杂志,2019,39(4):509-512.

[18] GHAZNAVI H, MAHMOODI K, SOLTANPOUR M S. A preliminary study of the association between the ABCA1 gene promoter DNA methylation and coronary artery disease risk[J]. Mol Biol Res Commun,2018, 7(2):59-65.

[19] SONG C X, SZULWACH K E, FU Y, et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine[J]. Nat Biotechnol,2011,29(1):68-72.

[20] PENG J, YANG Q, LI A, et al. Tetmethylcytosine dioxygenase2 inhibits atherosclerosis via upregulation of autophagy in ApoE-/- mice[J]. Oncotarget,2016,7(47):76423-76436.

[21] 刘保东,汪海林.真核生物基因组DNA甲基化和去甲基化分析[J].生命科学,2018,30(4):374-382.

[22] GILAT N, TABACHNIK T, SHWARTZ A, Single-molecule quantification of 5-hydroxymethylcytosine for diagnosis of blood and colon cancers[J]. Clinical Epigenetics,2017,9(1):70.

[23] 李琳,李杰,胡志希,等.早发冠心病血瘀证与血管紧张素转化酶基因单核苷酸多态性的相关性研究[J].中国中西医结合杂志,2015,35(6):686-690.

[24] 陈光,何浩强,刘咏梅,等.冠心病不稳定性心绞痛血瘀证患者IL-6基因甲基化研究及方法探讨[J].中国实验方剂学杂志,2017,23(19):23-27.

[25] 唐梅森.基于DNA单核苷酸多态性和甲基化修饰探讨早发冠心病血瘀证的相关易感基因的研究[D].长沙:湖南中医药大学,2015.

[26] TANG M S, HUANG Z D, XIANG Z J, et al. Research into relationship between estrogen receptor geneβpromoter regionmethylation status and blood stasis syndrome of premature coronary heart disease[J].中华中医药杂志,2015,30(5):1464-1466.

[27] 向忠军.基于甲基化修饰探讨加减养心通脉方对冠心病血瘀证及亚型CTNNB1、DES基因表达的影响研究[D].长沙:湖南中医药大学,2015.

[28] 郑静,金国琴.中药对衰老相关性疾病DNA甲基化的作用[J].中药药理与临床,2017,33(3):211-214.

[29] 康群甫,刘卫红,任攀,等.活血解毒中药对动脉粥样硬化小鼠血清PGI2/TXA2及DNA甲基化水平的干预作用[J].北京中医药,2016,35(4):309-314.

[30] WANG L, QIU X M, HAO Q, et al. Anti-inflammatory effects of a Chinese herbal medicine in atherosclerosis via estrogen receptorβ mediacing nitric oxide production and NF-κB suppression in endothelial cells[J]. Cell Death Dis,2013,4:1-13.

[31] 汤琛琛,刘亚敏,石玉琳,等.中药调控DNA甲基化修饰的研究进展[J].中国医药导报,2017,14(18):30-33.

[32] ANNA L, MACIEJ W, WIOLETA G, et al. Curcumin induces oxidation-dependent cell cycle arrest mediated by SIRT7 inhibition of rDNA transcription in human aortic smooth muscle cells[J]. Toxicology Letters,2015,233(3):227-238.

[33] 武庆娟,李军.miRNA及DNA甲基化与中药干预冠心病机制研究进展[J].世界中西医结合杂志,2019,14(3):437-440.

[34] 钟广伟,万玲,王东生,等.平肝潜阳方含药血清对血管紧张素Ⅱ诱导血管平滑肌细胞增殖、迁移及DNA甲基化水平的影响[J].中国中西医结合杂志,2016,36(5):580-585.

[35] ZHOU Q B, WU L Q, ZHANG Y, et al. Effects of Zhizi Chuanxiong Capsule on the abnormal methylation in rabbits with atherosclerosis[J]. Chin J Integr Med,2018,24(7):512-517.

[36] 尹伟娜.KLF5介导miR-155的表达和分泌以及通心络的干预作用[D].石家庄:河北医科大学,2016.

[37] 任攀,康群甫,周明学,等.当归芍药散对动脉粥样硬化小鼠的干预作用及DNA甲基转移酶1和PPAR-γ表达的影响[J].环球中医药,2017, 10(11):1328-1332.

[38] 黄海波.养心通脉方对早发冠心病血瘀证家系CHL1、ZEB2基因甲基化作用影响的研究[D].长沙:湖南中医药大学,2015.

[39] 程修平,宫丽鸿,李楠,等.稳斑汤辅助治疗对急性冠状动脉综合征痰浊血瘀证患者血浆血栓调节蛋白基因启动子甲基化的影响[J].中医杂志,2016,57(2):140-144.

相似文献/References:

[1]王春燕,王萍,王凤云,等.唐旭东运用失笑散治疗慢性萎缩性胃炎血瘀证经验[J].中国中医药信息杂志,2014,21(3):96.[doi:10.3969/j.issn.1005-5304.2014.03.031]
 [J].zhongguo zhongyiyao xinxi zazhi,2014,21(11):96.[doi:10.3969/j.issn.1005-5304.2014.03.031]
[2]刘雪涛,叶祖光.冠心病心肌缺血的中医治法方药研究概述[J].中国中医药信息杂志,2010,17(5):106.
[3]赵华云,王文会,郎江明,等.参七汤干预冠心病支架植入术后再狭窄临床研究[J].中国中医药信息杂志,2010,17(2):18.
 ZHAO Hua-yun,WANG Wen-hui,LANG Jiang-ming,et al.Clinical Study of Shenqi Decoction in Treating Restenosis after Implantation of Stents in Patients with Coronary Artery Disease[J].zhongguo zhongyiyao xinxi zazhi,2010,17(11):18.
[4]姚欣艳,谭元生,高晓峰,等.十味温胆汤加味治疗冠心病稳定型心绞痛气虚痰瘀证临床研究[J].中国中医药信息杂志,2009,16(1):15.
 YAO Xin-yan,TAN Yuan-sheng,GAO Xiao-feng,et al.Clinical Study of Shiwei Wendan Decoction in Treating Coronary Heart Disease Stable Angina Pectoris of Qi Deficiency and Stasis-phlegm Type[J].zhongguo zhongyiyao xinxi zazhi,2009,16(11):15.
[5]康兴霞,范平.怡心汤治疗冠心病心绞痛疗效观察[J].中国中医药信息杂志,2010,17(7):5.[doi:10.3969/j.issn.1005-5304.2010.07.003]
 KANG Xing-xia,FAN Ping.Clinical Observation of Yixin Tang in Treating Angina Pectoris of Coronary Heart Disease[J].zhongguo zhongyiyao xinxi zazhi,2010,17(11):5.[doi:10.3969/j.issn.1005-5304.2010.07.003]
[6]郎立和.补阳还五汤临证举隅[J].中国中医药信息杂志,2010,17(7):88.[doi:10.3969/j.issn.1005-5304.2010.07.044]
 [J].zhongguo zhongyiyao xinxi zazhi,2010,17(11):88.[doi:10.3969/j.issn.1005-5304.2010.07.044]
[7]颜乾麟.颜德馨审机论治冠心病经验[J].中国中医药信息杂志,2009,16(2):88.
 [J].zhongguo zhongyiyao xinxi zazhi,2009,16(11):88.
[8]胡木林,王忠,李涛,等.缺血性中风血瘀证患者MTHFR基因多态性研究[J].中国中医药信息杂志,2009,16(3):16.
 HU Mu-Lin,WANG Zhong,LI Tao,et al.Study on MTHFR C677T Polymorphism in Ischemic Stroke with Blood Stasis Syndrome[J].zhongguo zhongyiyao xinxi zazhi,2009,16(11):16.
[9]胡志希,袁肇凯,陈洁,等.早发冠心病血瘀证痰浊证面部光电血流容积特征及与一氧化氮、内皮素含量的相关研究[J].中国中医药信息杂志,2009,16(3):19.
 HU Zhi-xi,YUAN Zhao-kai,CHEN Jie,et al.Study on Characteristic of Photoelectric Facial Blood Flow Volume and Its Relation with NO and ET in Patients with Premature Coronary Heart Disease of Blood Stasis and Phlegm Syndrome[J].zhongguo zhongyiyao xinxi zazhi,2009,16(11):19.
[10]张玉辉.曹洪欣治疗疑难病证5则[J].中国中医药信息杂志,2009,16(3):77.
 [J].zhongguo zhongyiyao xinxi zazhi,2009,16(11):77.
[11]杨杰,王米渠,杜英杰,等.活血化瘀中药治疗冠心病血瘀证个案疗效评价及与凝血、血流异常相关基因的相关性[J].中国中医药信息杂志,2011,18(11):18.[doi:10.3969/j.issn.1005-5304.2011.11.007]
 YANG Jie,WANG Mi-qu,DU Ying-Jie,et al.Case Analysis of Chinese Herbs of Activating Blood and Removing Stasis in Treating Coronary Artery Disease and Blood Stasis Syndrome and Its Relationship with Abnormal Expressed Genes Relevant to Blood Coagulation and Bloodstream[J].zhongguo zhongyiyao xinxi zazhi,2011,18(11):18.[doi:10.3969/j.issn.1005-5304.2011.11.007]
[12]毛以林,李旭,彭素娟,等.冠心病血瘀证与高敏C-反应蛋白相关性研究[J].中国中医药信息杂志,2007,14(8):26.
 MAO Yi-lin,LI Xu,PENG Su-juan,et al.Study on the Relationship between Hs-CRP and the Blood Stasis Syndrome in Coronary Heart Disease[J].zhongguo zhongyiyao xinxi zazhi,2007,14(11):26.
[13]王阶,姜燕,杨保林.运用差异显示筛查冠心病血瘀证相关基因[J].中国中医药信息杂志,2005,12(2):84.
 WANG Jie,JIANG Yan,YANG Bao-lin.Screening the Correlation Genes of Blood Stasis Syndrome in Coronary Heart Disease with mRNA Differential Display[J].zhongguo zhongyiyao xinxi zazhi,2005,12(11):84.
[14]李琳,李杰,胡志希,等.冠心病血瘀证载脂蛋白E基因多态性与吸烟的交互作用关系探讨[J].中国中医药信息杂志,2014,21(8):130.[doi:10.3969/j.issn.1005-5304.2014.08.044]
 [J].zhongguo zhongyiyao xinxi zazhi,2014,21(11):130.[doi:10.3969/j.issn.1005-5304.2014.08.044]

备注/Memo

基金项目:国家自然科学基金(81673963、81874375);湖南省自然科学基金(2018JJ2298);湖南省教育厅重点项目(16A160);湖南省教育厅科研项目重点项目(60011120);湖南中医药大学中西医结合一流学科开放基金(2018ZXYJH23)

更新日期/Last Update:

2020-10-19